ALBUQUERQUE, N.M.--(BUSINESS WIRE)--In the November issue of the President’s Column, cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) thanked veterans for their contribution to the pilot clinical study of the Company’s CyPath® diagnostic assay for the detection of early-stage lung cancer. The November President’s Column can be found at www.biomoda.com.
